---
title: "Genelux (GNLX) news: going concern and offering"
url: "https://aibio.space/companies/genelux/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "GNLX going concern and offering news: Genelux prices $10.5 million underwritten offering of 3,000,000 shares at $3.50."
---

GNLX Genelux Corporation NASDAQ · United States

# Genelux (GNLX) news GNLX going concern and offering news

Financings · 2026-01-08

## [Genelux sells $20 million of stock at $3 a share to fund ovarian cancer phase 3](https://aibio.space/news/genelux-sells-20-million-stock-3-share-fund-ovarian-cancer-phase-3/)

Genelux sold 6,666,667 shares at $3.00 through Lucid Capital Markets, raising about $20.0 million gross. The oncolytic virus developer is running a phase 3 trial of Olvi-Vec in platinum-resistant ovarian cancer, and its China partner Newsoara holds the rights there.

## Latest Genelux news

1. 2025-03-25 Financings [Genelux prices $10.5 million underwritten offering of 3,000,000 shares at $3.50](https://aibio.space/news/genelux-prices-10-5-million-underwritten-offering-3-000-000-shares-3/) Net proceeds are about $9.1 million. The auditor has raised going-concern doubt, and preliminary year-end cash was $30.9 million.

## Genelux at a glance

- **Ticker**: GNLX

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $18.7 million

### Related companies

- [EOM Pharmaceutical Holdings](https://aibio.space/companies/eom-pharmaceutical/) OTC: IMUC
- [Immix Biopharma](https://aibio.space/companies/immix-biopharma/) NASDAQ: IMMX
- [Aardvark Therapeutics](https://aibio.space/companies/aardvark-therapeutics/) NASDAQ: AARD
- [CytomX Therapeutics](https://aibio.space/companies/cytomx-therapeutics/) NASDAQ: CTMX
- [AIM ImmunoTech](https://aibio.space/companies/aim-immunotech/) AMEX: AIM
- [Ligand Pharmaceuticals](https://aibio.space/companies/ligand-pharmaceuticals/) NASDAQ: LGND
- [Liminatus Pharma](https://aibio.space/companies/liminatus-pharma/) NASDAQ: LIMN
- [Pulmatrix](https://aibio.space/companies/pulmatrix/) NASDAQ: PULM

### Also on NASDAQ

- [BioVie](https://aibio.space/companies/biovie/) BIVI
- [Belite Bio](https://aibio.space/companies/belite-bio/) BLTE
- [DarioHealth](https://aibio.space/companies/dariohealth/) DRIO
- [Structure Therapeutics](https://aibio.space/companies/structure-therapeutics/) GPCR
- [MacroGenics](https://aibio.space/companies/macrogenics/) MGNX
- [Verrica Pharmaceuticals](https://aibio.space/companies/verrica-pharmaceuticals/) VRCA

## What Genelux does

Genelux is a late clinical-stage biopharmaceutical company developing next-generation oncolytic viral immunotherapies for aggressive and difficult-to-treat tumor types. Its lead candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified strain of the vaccinia virus designed to kill tumor cells and induce an immune response against each patient's tumor neoantigens. Genelux is evaluating Olvi-Vec in three clinical trials: a Phase 3 registrational trial in the U.S. in platinum-resistant/refractory ovarian cancer, a Phase 2 trial in the U.S. in recurrent non-small cell lung cancer, and a Phase 1b/2 trial in China in recurrent small cell lung cancer. Under its Newsoara License Agreement, Newsoara holds an exclusive license to Olvi-Vec in China, including mainland China, Taiwan, Hong Kong and Macau. The company operates a cGMP manufacturing facility in San Diego, California. Its CHOICE discovery platform has produced over 500 different versions of the vaccinia virus armed with greater than 110 transgenes, which the company intends to use to build a pipeline of further oncology candidates. Genelux says it intends to retain U.S. rights to its product candidates and to seek partnerships in geographies where it is unlikely to commercialize alone.

| Product or program | What it is | Stage |
|---|---|---|
| Olvi-Vec (ovarian cancer) | Oncolytic vaccinia virus given intraperitoneally for platinum-resistant/refractory ovarian cancer | Phase 3 |
| Olvi-Vec (non-small cell lung cancer) | Systemically administered oncolytic vaccinia virus for recurrent non-small cell lung cancer | Phase 2 |
| Olvi-Vec (small cell lung cancer) | Systemically administered oncolytic vaccinia virus for recurrent small cell lung cancer in China | Phase 1b/2 |

Summarised from the company's [10-K filed Mar 19, 2026](https://www.sec.gov/Archives/edgar/data/1231457/000149315226011616/form10-k.htm).

## Genelux annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$8,000](https://www.sec.gov/Archives/edgar/data/1231457/000149315226011616/) | [$8,000](https://www.sec.gov/Archives/edgar/data/1231457/000149315226011616/) |
| Research and development | [$19.9 million](https://www.sec.gov/Archives/edgar/data/1231457/000149315226011616/) | [$19.0 million](https://www.sec.gov/Archives/edgar/data/1231457/000149315226011616/) |
| Net income (loss) | [-$32.1 million](https://www.sec.gov/Archives/edgar/data/1231457/000149315226011616/) | [-$29.9 million](https://www.sec.gov/Archives/edgar/data/1231457/000149315226011616/) |
| Cash from operations | [-$25.3 million](https://www.sec.gov/Archives/edgar/data/1231457/000149315226011616/) | [-$21.2 million](https://www.sec.gov/Archives/edgar/data/1231457/000149315226011616/) |
| Cash and equivalents | [$5.3 million](https://www.sec.gov/Archives/edgar/data/1231457/000149315226037667/) | [$8.6 million](https://www.sec.gov/Archives/edgar/data/1231457/000149315226011616/) |
| Short-term investments |  | [$22.3 million](https://www.sec.gov/Archives/edgar/data/1231457/000149315225020874/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $9.2 million, plus short-term investments of $9.5 million, $18.7 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Analysis

- Opinion Negative view 2026-10-28 [Genelux has about 9 months of cash, a going concern warning and little outside support](https://aibio.space/analysis/genelux-has-about-9-months-cash-going-concern-warning-little/) Olvi-Vec is in a Phase 3 trial, but cash covers about 9 months at the recent burn. We think another raise is more likely than not.

Opinion, not personal investment advice. [All analysis](https://aibio.space/analysis/).

## Questions about Genelux

Has Genelux issued a going-concern warning?

Our latest story on this, dated Mar 25, 2025: "Genelux prices $10.5 million underwritten offering of 3,000,000 shares at $3.50". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/genelux-prices-10-5-million-underwritten-offering-3-000-000-shares-3/).

Has Genelux raised money recently?

Our latest story on this, dated Jan 8, 2026: "Genelux sells $20 million of stock at $3 a share to fund ovarian cancer phase 3". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/genelux-sells-20-million-stock-3-share-fund-ovarian-cancer-phase-3/).

What is the ticker symbol of Genelux?

Genelux Corporation trades under the ticker GNLX on NASDAQ.

Where is Genelux listed?

Genelux Corporation is listed on NASDAQ.

What is the SEC CIK of Genelux?

The SEC Central Index Key (CIK) for Genelux Corporation is 1231457. Its filings are on SEC EDGAR.

How many shares does Genelux have outstanding?

45,245,335 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13.

Which country or territory is Genelux listed under?

Our directory records Genelux Corporation under United States.

What does Genelux do?

Our directory classifies Genelux Corporation as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Genelux?

The ISIN recorded for Genelux Corporation is US36870H1032.

Does aibio.space cover Genelux?

aibio.space lists Genelux Corporation among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Genelux incorporated?

SEC records list its state or country of incorporation as DE.

What does Genelux develop?

Genelux is a late clinical-stage biopharmaceutical company developing next-generation oncolytic viral immunotherapies for aggressive and difficult-to-treat tumor types. Its lead candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified strain of the vaccinia virus designed to kill tumor cells and induce an immune response against each patient's tumor neoantigens.

What is Olvi-Vec (ovarian cancer) from Genelux?

Olvi-Vec (ovarian cancer): Oncolytic vaccinia virus given intraperitoneally for platinum-resistant/refractory ovarian cancer Stage: Phase 3.

What is Olvi-Vec (non-small cell lung cancer) from Genelux?

Olvi-Vec (non-small cell lung cancer): Systemically administered oncolytic vaccinia virus for recurrent non-small cell lung cancer Stage: Phase 2.

What was Genelux's revenue last year?

$8,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.

## Investor discussion: Genelux

Members talk about Genelux (GNLX). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Genelux, newest first. Each line links the filing it comes from.

1. 2026-08-13 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1231457/000149315226037667/form10-q.htm)
2. 2026-03-19 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1231457/000149315226011616/form10-k.htm)
3. 2026-03-19 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1231457/000149315226011649/form8-k.htm)
4. 2026-01-07 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1231457/000149315226000825/form424b5.htm)
5. 2025-03-25 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1231457/000164117225000642/ex99-1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:GNLX on TradingView](https://www.tradingview.com/symbols/NASDAQ-GNLX/).

## SEC filings and registration

- **SEC name**: GENELUX Corp

- **CIK**: 1231457

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: GNLX (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

- **Business address**: 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361

- **Phone**: 805-267-9889

- **Shares outstanding**: 45,245,335 as of 2026-08-11 (10-Q filed 2026-08-13)

### Recent filings (8-K and 6-K are the company's own announcements)

- [10-Q](https://www.sec.gov/Archives/edgar/data/1231457/000149315226037667/form10-q.htm) filed 2026-08-13
- [8-K](https://www.sec.gov/Archives/edgar/data/1231457/000149315226029607/form8-k.htm) filed 2026-06-22
- [10-Q](https://www.sec.gov/Archives/edgar/data/1231457/000149315226021710/form10-q.htm) filed 2026-05-07
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/1231457/000149315226019473/formdef14a.htm) filed 2026-04-29
- [424B5](https://www.sec.gov/Archives/edgar/data/1231457/000149315226011696/form424b5.htm) filed 2026-03-19
- [8-K](https://www.sec.gov/Archives/edgar/data/1231457/000149315226011649/form8-k.htm) filed 2026-03-19
- [10-K](https://www.sec.gov/Archives/edgar/data/1231457/000149315226011616/form10-k.htm) filed 2026-03-19
- [8-K](https://www.sec.gov/Archives/edgar/data/1231457/000149315226004755/form8-k.htm) filed 2026-02-02

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001231457), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Genelux Corporation is a public biotech or pharmaceutical company listed on NASDAQ under the ticker GNLX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Genelux Corporation

- **Ticker**: GNLX

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US36870H1032

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-GNLX/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/genelux/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Genelux (GNLX) news: going concern and offering", 2026-10-31, https://aibio.space/companies/genelux/